Compare · DICE vs LLY
DICE vs LLY
Side-by-side comparison of DICE Therapeutics Inc. (DICE) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DICE and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 1783.2x DICE ($608.6M).
- Over the past year, DICE is down 2.8% and LLY is up 53.2% - LLY leads by 56.0 points.
- LLY has hit the wire 10 times in the past 4 weeks while DICE has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 12 for DICE).
- Company
- DICE Therapeutics Inc.
- Eli Lilly and Company
- Price
- $24.45-2.78%
- $1152.46-0.00%
- Market cap
- $608.6M
- $1.09T
- 1M return
- -2.78%
- -10.00%
- 1Y return
- -2.78%
- +53.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 10
- Recent ratings
- 12
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest DICE
- SEC Form 15-12G filed by DICE Therapeutics Inc.
- SEC Form EFFECT filed by DICE Therapeutics Inc.
- SEC Form 4 filed by Ra Capital Management, L.P.
- SEC Form SC 13D/A filed by DICE Therapeutics Inc. (Amendment)
- SEC Form 4: Tetlow Sharon returned 49,841 shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Simson Jake
- SEC Form 4: Scopa James Paul returned 40,921 shares to the company, closing all direct ownership in the company
- SEC Form 4: Robertson Scott M. returned 198,000 shares to the company, closing all direct ownership in the company
- SEC Form 4: Scheller Richard H returned 8,427 shares to the company, closing all direct ownership in the company
- SEC Form 4: Timothy Lu returned 152,285 shares to the company, closing all direct ownership in the company
Latest LLY
- U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
- Eli Lilly upgraded by Berenberg with a new price target
- Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
- EVP, Global Quality Seymour Melissa gifted 29 shares, decreasing direct ownership by 3% to 1,038 units (SEC Form 4)
- Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study